Trial Profile

A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Temsirolimus
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms TemPa

Most Recent Events

20 Sep 2019 Status changed from active, no longer recruiting to completed.
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
10 Feb 2018 Primary endpoint has not been met. (Progression Free Survival (PFS)) as per result presented at the 2018 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com